Title: Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma

David Price[1,2,3], Sarah Burkill[1,2], Eileen Wang[4,5], Michael E. Wechsler[6], Eve Denton[7,8], Trung N. Tran[9], Neil Martin[9,10], Rohit Katial[9], Peter Barker[9] ,Jorge Maspero[11,12], Mark Hew[13,14], Guy Brusselle[15,16], George C. Christoff[17], Mohsen Sadatsafavi[18], Carlos A. Torres-Duque[19], Celeste M. Porsbjerg[20], Charlotte Ulrik[21], Susanne Hansen[22,23], Alan Altraja[24], Arnaud Bourdin[25], Nikolaos G. Papadopoulos[26,27], Konstantinos Kostikas[28], Sundeep Salvi[29], Richard W. Costello[30], Puggioni Francesca[31,32] , Takashi Iwanaga[33], Chin Kook Rhee[34], Mona Al-Ahmad[35], Désirée Larenas-Linnemann[36], João A. Fonseca[37], Borja G. Cosio[38], Mariko Koh Siyue[39,40] , Bruce Kirenga[41], Chau-Chyun Sheu[42,43], Ming-Ju Tsai[42,43], Bassam Mahboub[44,45], John Busby[46], Liam G. Heaney[47], Paul E. Pfeffer[48,49], Pujan H Patel[50], Flavia Hoyte[4,5], Yang Liu[51], Juntao Lyu[1,52], Celine Goh[1,2], Thendral Uthaman,[1] William Henley[1,2,53], on behalf of the ISAR EMBER working group.

Affiliations: [1]Observational and Pragmatic Research Institute, Singapore; [2]Optimum Patient Care Global, Cambridge, UK; [3]Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; [4]Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, USA; [5]Division of Allergy & Clinical Immunology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; [6]NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health, Denver, CO, USA; [7]Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, Australia; [8]Public Health and Preventive Medicine, Monash University, Australia; [9]AstraZeneca, Gaithersburg, MD, USA; [10]University of Leicester, Leicester, UK; [11]Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation; [12]University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Argentina; [13]Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia; [14]Public Health and Preventive Medicine, Monash University, Melbourne, Australia; [15]Departments of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; [16]Department of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; [17]Medical University-Sofia, Faculty of Public Health, Sofia, Bulgaria; [18]Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; [19]Fundación Neumológica Colombiana, Bogotá, Colombia; [20]Respiratory Research Unit, Copenhagen University Hospital-Bispebjerg; [21]Respiratory Research Unit, Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark; [22]Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark; [23]Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; [24]Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia; [25]PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France; [26]Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK; [27]Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; [28]Respiratory Medicine Department, University of Ioannina, Greece; [29]Pulmocare Research and Education Foundation, Pune, India; [30]Clinical Research Centre, Smurfit Building Beaumont Hospital, Department of Respiratory Medicine, RCSI, Dublin, Ireland; [31]Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy; [32]Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; [33]Center for General Medical Education and Clinical Training, Kindai University Hospital, Osakasayama, Japan; [34]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; [35]Microbiology Department, Faculty of Medicine, Kuwait University, Al-Rashed Allergy Center, Ministry of Health, Kuwait; [36]Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, Mexico; [37]Health Information and Decision Sciences Department (MEDCIDS) & Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine of University of Porto, Porto, Portugal; [38]Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain; [39]Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore; [40]SingHealth Duke-NUS Lung Centre, Singapore; [41]Makerere University Lung Institute, Kampala Uganda; [42]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University,

Taiwan; [43]Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan; [44]College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; [45]Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; [46]Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland; [47]Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland; [48]Department of Respiratory Medicine, Barts Health NHS Trust, London, UK; [49]Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; [50]Respiratory Medicine, Royal Brompton Hospital, London, UK; [51]Consulting, Strategy AI & Transformation, Deloitte, Brisbane, Australia; [52]Optimum Patient Care, Queensland, Australia; [53]Health Statistics Group, Institute of Health Research, University of Exeter Medical School, Exeter, United Kingdom.

Introduction/Background: Biomarker-defined clusters of severe asthma patients were previously identified via hierarchical cluster analysis; a cluster of older females with low-to-medium Type 2 (T2) biomarkers was characterized (Denton, E. et al. *J Allergy Clin Immunol Pract* 2021;9:2680-8.e7).

Aims and Objectives: To describe biomarker-defined clusters (blood eosinophil counts [BEC], FeNO, and serum IgE [IgE]) in severe asthma patients, and characterize T2-low asthma.

Methods: Patients in the International Severe Asthma Registry (ISAR) with biomarker data were included, regardless of biologic use. The Gaussian finite mixture 5-cluster model was used to perform cluster analyses using BEC, FeNO, IgE and demographic variables standardized by z score. The prespecified thresholds for low biomarkers were BEC <300cells/μL, FeNO <25ppb and IgE <75 IU/mL.

Results: Of 4459 patients, five clusters were identified. Cluster 1 had females with low T2 biomarkers. Cluster 2 had high BEC and FeNO; Cluster 3, triple T2 biomarker high; Cluster 4, high BEC; Cluster 5, high IgE.

Figure: Median (IQR) biomarker levels and characteristics of clusters

	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5	
N	747	1038	357	1,503	814	$p \leq 0.001$
BEC (cells/μL)	200 (200)	850 (752)	1160 (2900)	400 (400)	300 (300)	
FeNO (ppb)	16 (12)	93 (75)	52 (77)	37 (36)	24 (22)	
IgE (IU/mL)	28 (40)	304 (362)	1669 (2525)	115 (126)	650 (657)	
Females	73%	56%	54%	63%	58%	
Age	55 (21)	54 (20)	55 (23)	56 (19)	52 (22)	
BMI	29 (10)	27 (7)	26 (7)	29 (8)	28 (9)	

Conclusions: In line with previous findings, a cluster with females and low biomarkers suggested low T2 involvement. The other 4 clusters varied in biomarker elevations, highlighting the complexity of T2 inflammatory involvement in severe asthma.

Current length of abstract: 1758 characters

Maximum Length of an abstract: 1810 characters